Letters1 September 1994Acyclovir and Ganciclovir in CytomegalovirusGary B. Moss, MDGary B. Moss, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-5-199409010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their study, Singh and colleagues [1] propose “to assess the efficacy of high-dose oral acyclovir compared with preemptive, short-course ganciclovir therapy … to prevent CMV [cytomegalovirus] disease in live transplant patients.” Although their data strongly support the efficacy of ganciclovir over acyclovir in these patients, they do not directly compare these two medications.Each patient was randomly assigned to receive either high-dose oral acyclovir or no prophylaxis. If patients in either group later developed evidence of active CMV infection, they received a short course of gancyclovir to prevent progression of disease.Because all patients in both ...Reference1. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalorvirus disease in liver transplant recipients. A randomized trial. Ann Intern Med. 1994; 120:375-81. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1994Volume 121, Issue 5Page: 385KeywordsCytomegalovirus infectionInfectious diseasesLiver transplantationProphylaxisRandomized trials Issue Published: 1 September 1994 CopyrightCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...